Abstract | OBJECTIVE: METHODS: The effectiveness of the combination of ritonavir and bortezomib on renal cancer cells (Caki-1, ACHN, 786-O, 769-P) was assessed by MTS assay, colony formation assay, cell cycle analysis, and annexin-V assay. In vivo efficacy was evaluated using mice subcutaneous tumor models. Induction of ER stress, protein ubiquitination, histone acetylation, and changes in the expression of histone deacetylase (HDAC) were evaluated by Western blotting. RESULTS:
Ritonavir in combination with bortezomib induced apoptosis and inhibited renal cancer growth synergistically at clinically feasible concentrations. In subcutaneous tumor models using Caki-1 cells, 10-day treatment with the combination was well tolerated and inhibited tumor growth significantly. Ritonavir induced ER stress and the combination enhanced protein ubiquitination synergistically. The combination was also found to induce histone acetylation by suppressing the HDAC expression. CONCLUSION:
|
Authors | Akinori Sato, Takako Asano, Keiichi Ito, Tomohiko Asano |
Journal | Urology
(Urology)
Vol. 79
Issue 4
Pg. 966.e13-21
(Apr 2012)
ISSN: 1527-9995 [Electronic] United States |
PMID | 22296623
(Publication Type: Journal Article)
|
Copyright | Copyright © 2012 Elsevier Inc. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- Boronic Acids
- HIV Protease Inhibitors
- Histones
- Pyrazines
- Ubiquitinated Proteins
- Bortezomib
- Ritonavir
|
Topics |
- Acetylation
(drug effects)
- Animals
- Antineoplastic Agents
(pharmacology)
- Apoptosis
(drug effects)
- Boronic Acids
(pharmacology)
- Bortezomib
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Dose-Response Relationship, Drug
- Drug Synergism
- Endoplasmic Reticulum
(drug effects)
- HIV Protease Inhibitors
(pharmacology)
- Histones
(metabolism)
- Mice
- Mice, Nude
- Pyrazines
(pharmacology)
- Ritonavir
(pharmacology)
- Ubiquitinated Proteins
(drug effects)
- Ubiquitination
(drug effects)
- Xenograft Model Antitumor Assays
|